Entrada Therapeutics (TRDA) Current Leases (2022 - 2026)

Entrada Therapeutics' Current Leases history runs 5 years deep, the most recent figure standing at $4.3 million for Q1 2026.

• In Q1 2026, Current Leases fell 34.24% year-over-year to $4.3 million; the TTM figure through Mar 2026 stood at $4.3 million (down 34.24% YoY), while the FY2025 annual figure was $4.1 million, down 45.26% from the prior year.
• Current Leases was $4.3 million for Q1 2026 at Entrada Therapeutics, up from $4.1 million in the prior quarter.
• In the past five years, Current Leases ranged from a high of $8.6 million in Q2 2024 to a low of $4.1 million in Q4 2025.
• Historically, Current Leases has averaged $7.0 million across 5 years, with a median of $7.6 million in 2024.
• The sharpest annual moves came in 2024 and 2025: Current Leases gained 16.87% in 2024, then tumbled 45.26% in 2025.
• A 5-year view of Current Leases shows it stood at $8.4 million in 2022, then decreased by 5.91% to $7.9 million in 2023, then decreased by 4.43% to $7.6 million in 2024, then slumped by 45.26% to $4.1 million in 2025, then gained by 3.46% to $4.3 million in 2026.
• The last three Current Leases figures came in at $4.3 million (Q1 2026), $4.1 million (Q4 2025), and $4.4 million (Q3 2025), per Business Quant data.